BACKGROUND: Individuals treated with the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibit a reduction in both LDL cholesterol and apolipoprotein B (ApoB) in response to monotherapy or combination therapy with a statin. It is not clear how anacetrapib exerts these effects; therefore, the goal of this study was to determine the kinetic mechanism responsible for the reduction in LDL and ApoB in response to anacetrapib. METHODS: We performed a trial of the effects of anacetrapib on ApoB kinetics. Mildly hypercholesterolemic subjects were randomized to background treatment of either placebo (n = 10) or 20 mg atorvastatin (ATV) (n = 29) for 4 weeks. All subjects then added 100 mg anacetrapib to background treatment for 8 weeks. Following each study period, subjects underwent a metabolic study to determine the LDL-ApoB-100 and proprotein convertase subtilisin/kexin type 9 (PCSK9) production rate (PR) and fractional catabolic rate (FCR). RESULTS:Anacetrapib markedly reduced the LDL-ApoB-100 pool size (PS) in both the placebo and ATV groups. These changes in PS resulted from substantial increases in LDL-ApoB-100 FCRs in both groups. Anacetrapib had no effect on LDL-ApoB-100 PRs in either treatment group. Moreover, there were no changes in the PCSK9 PS, FCR, or PR in either group. Anacetrapib treatment was associated with considerable increases in the LDL triglyceride/cholesterol ratio and LDL size by NMR. CONCLUSION: These data indicate that anacetrapib, given alone or in combination with a statin, reduces LDL-ApoB-100 levels by increasing the rate of ApoB-100 fractional clearance. TRIAL REGISTRATION: ClinicalTrials.gov NCT00990808. FUNDING: Merck & Co. Inc., Kenilworth, New Jersey, USA. Additional support for instrumentation was obtained from the National Center for Advancing Translational Sciences (UL1TR000003 and UL1TR000040).
RCT Entities:
BACKGROUND: Individuals treated with the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibit a reduction in both LDL cholesterol and apolipoprotein B (ApoB) in response to monotherapy or combination therapy with a statin. It is not clear how anacetrapib exerts these effects; therefore, the goal of this study was to determine the kinetic mechanism responsible for the reduction in LDL and ApoB in response to anacetrapib. METHODS: We performed a trial of the effects of anacetrapib on ApoB kinetics. Mildly hypercholesterolemic subjects were randomized to background treatment of either placebo (n = 10) or 20 mg atorvastatin (ATV) (n = 29) for 4 weeks. All subjects then added 100 mg anacetrapib to background treatment for 8 weeks. Following each study period, subjects underwent a metabolic study to determine the LDL-ApoB-100 and proprotein convertase subtilisin/kexin type 9 (PCSK9) production rate (PR) and fractional catabolic rate (FCR). RESULTS:Anacetrapib markedly reduced the LDL-ApoB-100 pool size (PS) in both the placebo and ATV groups. These changes in PS resulted from substantial increases in LDL-ApoB-100 FCRs in both groups. Anacetrapib had no effect on LDL-ApoB-100 PRs in either treatment group. Moreover, there were no changes in the PCSK9 PS, FCR, or PR in either group. Anacetrapib treatment was associated with considerable increases in the LDL triglyceride/cholesterol ratio and LDL size by NMR. CONCLUSION: These data indicate that anacetrapib, given alone or in combination with a statin, reduces LDL-ApoB-100 levels by increasing the rate of ApoB-100 fractional clearance. TRIAL REGISTRATION: ClinicalTrials.gov NCT00990808. FUNDING: Merck & Co. Inc., Kenilworth, New Jersey, USA. Additional support for instrumentation was obtained from the National Center for Advancing Translational Sciences (UL1TR000003 and UL1TR000040).
Authors: Dawn E Telford; Brian G Sutherland; Jane Y Edwards; Joseph D Andrews; P Hugh R Barrett; Murray W Huff Journal: J Lipid Res Date: 2006-11-27 Impact factor: 5.922
Authors: Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer Journal: N Engl J Med Date: 2007-11-05 Impact factor: 91.245
Authors: Alexander Thompson; Emanuele Di Angelantonio; Nadeem Sarwar; Sebhat Erqou; Danish Saleheen; Robin P F Dullaart; Bernard Keavney; Zheng Ye; John Danesh Journal: JAMA Date: 2008-06-18 Impact factor: 56.272
Authors: Daniel Bloomfield; Gary L Carlson; Aditi Sapre; Diane Tribble; James M McKenney; Thomas W Littlejohn; Christine McCrary Sisk; Yale Mitchel; Richard C Pasternak Journal: Am Heart J Date: 2008-12-20 Impact factor: 4.749
Authors: Rajesh Krishna; Matt S Anderson; Arthur J Bergman; Bo Jin; Marissa Fallon; Josee Cote; Kim Rosko; Cynthia Chavez-Eng; Ryan Lutz; Daniel M Bloomfield; Maria Gutierrez; James Doherty; Fredrick Bieberdorf; Jeffrey Chodakewitz; Keith M Gottesdiener; John A Wagner Journal: Lancet Date: 2007-12-08 Impact factor: 79.321
Authors: Evan A Stein; Eli M Roth; James M Rhyne; Tracy Burgess; David Kallend; Jennifer G Robinson Journal: Eur Heart J Date: 2010-01-22 Impact factor: 29.983
Authors: Gissette Reyes-Soffer; John S Millar; Colleen Ngai; Patricia Jumes; Ellie Coromilas; Bela Asztalos; Amy O Johnson-Levonas; John A Wagner; Daniel S Donovan; Wahida Karmally; Rajasekhar Ramakrishnan; Stephen Holleran; Tiffany Thomas; Richard L Dunbar; Emil M deGoma; Hashmi Rafeek; Amanda L Baer; Yang Liu; Michael E Lassman; David E Gutstein; Daniel J Rader; Henry N Ginsberg Journal: Arterioscler Thromb Vasc Biol Date: 2016-03-10 Impact factor: 8.311
Authors: Gissette Reyes-Soffer; Byoung Moon; Antonio Hernandez-Ono; Marija Dionizovik-Dimanovski; Marija Dionizovick-Dimanovski; Jhonsua Jimenez; Joseph Obunike; Tiffany Thomas; Colleen Ngai; Nelson Fontanez; Daniel S Donovan; Wahida Karmally; Stephen Holleran; Rajasekhar Ramakrishnan; Robert S Mittleman; Henry N Ginsberg Journal: Sci Transl Med Date: 2016-01-27 Impact factor: 17.956